US 12,453,760 B2
Enhanced therapeutic usage of a purine nucleoside phosphorylase or nuceloside hydrolase prodrug
William B. Parker, Birmingham, AL (US); and Eric J. Sorscher, Birmingham, AL (US)
Assigned to The UAB Research Foundation, Birmingham, AL (US); and Southern Research Institute, Birmingham, AL (US)
Filed by The UAB Research Foundation, Birmingham, AL (US); and Southern Research Institute, Birmingham, AL (US)
Filed on Oct. 15, 2021, as Appl. No. 17/502,101.
Application 16/100,343 is a division of application No. 14/000,367, granted, now 10,080,784, issued on Sep. 25, 2018, previously published as PCT/US2012/025816, filed on Feb. 20, 2012.
Application 17/502,101 is a continuation of application No. 16/100,343, filed on Aug. 10, 2018, abandoned.
Claims priority of provisional application 61/444,261, filed on Feb. 18, 2011.
Prior Publication US 2022/0031817 A1, Feb. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/47 (2006.01); A61K 9/06 (2006.01); A61K 9/16 (2006.01); A61K 31/7076 (2006.01); A61K 38/45 (2006.01); A61K 38/46 (2006.01); A61K 48/00 (2006.01)
CPC A61K 38/47 (2013.01) [A61K 9/06 (2013.01); A61K 9/1641 (2013.01); A61K 9/1647 (2013.01); A61K 31/7076 (2013.01); A61K 38/45 (2013.01); A61K 38/465 (2013.01); A61K 48/00 (2013.01); Y02A 50/30 (2018.01)] 9 Claims
 
1. A method of treating a human subject having a solid tumor comprising:
administering an adenoviral vector encoding a purine nucleoside phosphorylase derived from E. coli (Ad/PNP) directly into the solid tumor; and
administering a prodrug directly into the solid tumor, wherein the prodrug is converted to a purine base cytotoxic to cells of the solid tumor;
wherein the prodrug is administered at least once a day for 3 consecutive days following administration of Ad/PNP;
wherein the prodrug is fludarabine phosphate (F-araAMP); and,
administering to the solid tumor X-ray radiation at least 3 hours after administration of the prodrug on each of the 3 consecutive days.